Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-6306 + FOLFIRI in advanced solid tumors
NCT05147350Phase 1Terminated
- Sponsor
- Debiopharm
- Start
- Aug 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of lunresertib in colorectal cancer (CRC), gastrointestinal cancer and esophageal cancer, sponsored by Debiopharm. Primary endpoints: Safety and Tolerability of RP-6306 in Combination With FOLFIRI up to 1.5 years, Maximum Tolerated Dose at 28 days and 1 more. Started Aug 2022; status: terminated.
02
Drugs
lunresertib
03
Conditions
colorectal cancer (CRC)gastrointestinal canceresophageal cancer
Beyond the preview
Go deeper on NCT05147350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147350.